Injection-free exenatide improves diabetes markers

10/3/2012 | Healio

Type 2 diabetes patients who received the injection-free exenatide ITCA 650 attained significant improvements in body weight, A1C, fasting plasma glucose and postprandial glucose levels, with greater effects seen in those who received higher doses than those who took a lower dose. However, researchers said 40 mcg and 60 mcg doses of ITCA 650 were better tolerated compared with the 80 mcg dose. The findings were presented at the European Association for the Study of Diabetes meeting.

View Full Article in:

Healio

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC